StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Enliven Therapeutics's total assets was $910.22M at Jun 30, 2026. For fiscal 2025 it was $476.17M, up 46.2% from the year before. The highest annual figure on record is $476.17M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$476.17M+46.2%
FY2024Dec 31, 2024$325.76M+19.8%
FY2023Dec 31, 2023$271.87M+226.4%
FY2022Dec 31, 2022$83.30M-11.1%
FY2021Dec 31, 2021$93.65M+3.1%
FY2020Dec 31, 2020$90.84M+172.8%
FY2019Dec 31, 2019$33.30M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$910.22M+80.6%
Q1 FY2026Mar 31, 2026$464.85M+53.6%
Q4 FY2025Dec 31, 2025$476.17M+46.2%
Q3 FY2025Sep 30, 2025$490.88M+60.7%
Q2 FY2025Jun 30, 2025$503.89M+54.1%
Q1 FY2025Mar 31, 2025$302.57M-11.7%
Q4 FY2024Dec 31, 2024$325.76M+19.8%
Q3 FY2024Sep 30, 2024$305.43M+11.5%
Q2 FY2024Jun 30, 2024$327.04M+13.4%
Q1 FY2024Mar 31, 2024$342.78M+13.2%
Q4 FY2023Dec 31, 2023$271.87M+226.4%
Q3 FY2023Sep 30, 2023$274.04M+363.7%
Q2 FY2023Jun 30, 2023$288.50M+346.1%
Q1 FY2023Mar 31, 2023$302.87M+271.2%
Q4 FY2022Dec 31, 2022$83.30M-11.1%
Q3 FY2022Sep 30, 2022$59.10M-44.8%
Q2 FY2022Jun 30, 2022$64.67M-10.8%
Q1 FY2022Mar 31, 2022$81.60M-0.1%
Q4 FY2021Dec 31, 2021$93.65M+3.1%
Q3 FY2021Sep 30, 2021$107.03M+6.8%
Q2 FY2021Jun 30, 2021$72.47M-34.9%
Q1 FY2021Mar 31, 2021$81.69M-26.0%
Q4 FY2020Dec 31, 2020$90.84M+172.8%
Q3 FY2020Sep 30, 2020$100.18M–
Q2 FY2020Jun 30, 2020$111.32M–
Q1 FY2020Mar 31, 2020$110.32M–
Q4 FY2019Dec 31, 2019$33.30M–

More Enliven Therapeutics figures

See a number that looks wrong?